These trials investigated the efficacy and safety of finerenone, on top of maximum tolerated labelled dose of an angiotensin‐converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB), on kidney and cardiovascular outcomes in patients with mild‐to‐severe chronic kidney disease (CKD) and type 2 diabetes (T2D). This evidence concerns the gene ACE and chronic kidney disease.